Recently, the clinical trial application for voricipamab injection (aqueous formulation), independently developed by Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), for "reducing the risk of acute attacks in gout patients in the initial stage of uric acid-lowering therapy" has been officially approved. This means that voricipamab is expected to provide a novel intervention for preventing acute attacks in gout patients at the critical stage of initiating uric acid-lowering therapy. If the clinical trial is successful, it may fill the gap in precision anti-inflammatory treatment for gout in my country.

According to statistics, there are more than 177 million people with hyperuricemia and more than 30 million people with gout in China, and the incidence rate is trending younger [1] . Gout is a common inflammatory joint disease caused by the deposition of monosodium urate (MSU) crystals. Repeated gout attacks may lead to joint damage and multi-system complications.
Long-term uric acid-lowering therapy is key to curing gout. However, after patients start taking uric acid-lowering drugs, fluctuations in blood uric acid levels and the dissolution of tophi or urate crystals inside and outside the joints can easily trigger acute attacks, especially in the first 3 to 6 months of uric acid-lowering therapy, when approximately 12% to 61% of patients may experience acute gout attacks [2,3] . Existing drugs for preventing acute gout attacks need improvement in terms of safety, efficacy, and patient compliance, and new treatment drugs are urgently needed in clinical practice.

Fuxinqibaizumab is a fully human anti-interleukin-1β (IL-1β) monoclonal antibody independently developed by Jinsai Pharmaceutical. It can precisely block IL-1β, a key inflammatory factor that triggers acute gout attacks. It can not only inhibit the continuous spread of the inflammatory response during an acute gout attack, but also inhibit the initiation of an acute gout attack.

It is worth noting that voxinqimab is actively expanding its indications. Previously, voxinqimab injection (aqueous formulation) has been approved for clinical trials in endometriosis (EM) and non-infectious uveitis (NIU); its indication for acute gouty arthritis was approved for marketing on April 29, 2026. Furthermore, voxinqimab injection (powder) has been approved for clinical trials in connective tissue disease-associated interstitial lung disease (CTD-ILD) and systemic juvenile idiopathic arthritis (sJIA), and its indication for acute gouty arthritis was approved for marketing on June 30, 2025.

To date, fosinocyclophosphamide has received clinical trial approval or marketing authorization in multiple autoimmune and inflammatory disease areas, further enhancing Jinsai Pharmaceutical's comprehensive portfolio in the immunology field. The company will continue to be clinically value-driven, providing patients with more diverse treatment options.

statement:
1. The development of innovative drugs is high-risk, and there is uncertainty regarding the results of clinical trials and final approval.
2. This news is intended to share cutting-edge research and development information and is intended for reference only by medical and health professionals. It is not for advertising purposes.
3. Jinsai Pharmaceutical does not recommend the use of any unapproved drugs or indications.

References:
1. CBN Data, "2021 China High Uric Acid and Gout Trend White Paper" https://pdf.dfcfw.com/pdf/H3_AP202104231487186153_1.pdf?1619175552000.pdf
2. Chinese Society of Endocrinology. Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout in China (2019) [J]. Chinese Journal of Endocrinology and Metabolism, 2020, 36(01):1-13.
3. Xu Dong, et al. Guidelines for the diagnosis and treatment of gout [J]. Chinese Journal of Internal Medicine, 2023, 62(9):1068-1076.
https://bydrug.pharmcube.com/news/detail/eefdc52e985795d9125e6558cfe59328